BARGOU RALF ET AL: "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 321, no. 5891, 15 August 2008 (2008-08-15), pages 974-977, XP002615656, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1158545 (B1)

WILSON et al.: "Novel disease targets and management approaches for diffuse large B-cell lymphoma", Leukemia & Lymphoma, vol. 51, no. S1, August 2010 (2010-08), pages 1-10, (B2)

QUINTÁS-CARDAMA ALFONSO ET AL: "Investigational immunotherapeutics for B-cell malignancies.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 FEB 2010 LNKD- PUBMED:20048186, vol. 28, no. 5, 10 February 2010 (2010-02-10), pages 884-892, XP009157966, ISSN: 1527-7755 (B1)

SOPHIE DUPIRE ET AL: "Targeted treatment and new agents in diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 92, no. 1, 1 July 2010 (2010-07-01), pages 12-24, XP55023306, ISSN: 0925-5710, DOI: 10.1007/s12185-010-0609-6 (B1)

WILSON WYNDHAM H ET AL: "Novel disease targets and management approaches for diffuse large B-cell lymphoma", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 51, no. supplement 1, 1 August 2010 (2010-08-01), pages 1-10, XP008135253, ISSN: 1042-8194, DOI: 10.3109/10428194.2010.500045 (B1)

WO-A1-2007/068354 (B1)

WO-A1-2011/051307 (B1)

"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4.03)", U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES, 14 June 2010 (2010-06-14), pages 1-3 ,129-139,196, (B2)

"Micromet ASH Update", Micromet Presentation, 7 December 2010 (2010-12-07), pages 1-28, (B2)

"Micromet's Blinatumomab Produces High Objective Response Rate in Spectrum of Relapsed NonHodgkin's Lymphoma Patients", Micromet Press Release, 6 December 2010 (2010-12-06), pages 1-2, (B2)

BRANDL et al.: "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody", Cancer Immunology Immunotherapy, vol. 56, no. 10, 20 February 2007 (2007-02-20), pages 1551-1563, (B2)

CHUNG C.H.: "Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy", The Oncologist, vol. 13, no. 6, June 2008 (2008-06), pages 725-732, (B2)

COIFFIER et al.: "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study", Blood, vol. 92, no. 6 , pages 1927-1932, (B2)

DAVIS et al.: "Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab", Journal of Clinical Oncology, vol. 17, no. 6, June 1999 (1999-06), pages 1851-1857, (B2)

GOEBELER, M et al.: "BLINATUMOMAB (CD3/CD19 BITE I ANTIBODY) RE SUL TS IN A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED NONHODGKINLYMPHOMA (NHL) INCLUDING MCL AND DLBCL", Annals Oncology, vol. 22, no. Suppl 4, June 2011 (2011-06), (B2)

SEBASTIAN et al.: "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM anti-CD3): a phase I study", Cancer Immunology Immunotherapy, vol. 56, no. 10, 2007, pages 1637-1644, (B2)

Thomson Reuters: "MITI - Micromet Inc. call to review results presented at 2010 ASHAnnual Meeting", Thomson Street Events, 7 December 2010 (2010-12-07), pages fp-12, (B2)

NG ET AL: "Diffuse Large B-Cell Lymphoma", SEMINARS IN RADIATION ONCOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 17, no. 3, 23 June 2007 (2007-06-23), pages 169-175, XP022128313, ISSN: 1053-4296, DOI: 10.1016/J.SEMRADONC.2007.02.002 (B1)